Mineralys Therapeutics, Inc. MLYS

Mineralys Therapeutics announced that long-term efficacy and safety data from Transform-HTN, its open-label extension of lorundrostat, will be presented as late-breaking science at the American Heart Association Scientific Sessions 2026 in Chicago. The session on November 8 features Manish Saxena presenting Transform-HTN: Long-Term Efficacy and Safety of Lorundrostat, a Novel Aldosterone Synthase Inhibitor, in Uncontrolled Hypertension. Transform-HTN (NCT05968430) follows patients who completed parent studies to assess safety, efficacy and tolerability, focusing on changes in automated office systolic BP. Mineralys notes lorundrostat achieved 40-70% plasma aldosterone reduction in hypertension and cites six late-stage trials, including the Phase 3 Launch-HTN and Phase 2 Advance-HTN programs. The company emphasizes its focus on aldosterone-driven hypertension and related comorbidities such as CKD and OSA. Shows potential credibility and investor interest impact from long-term data presentation, though no immediate regulatory or commercial milestones are declared.

Mineralys Therapeutics (MLYS) released its Q2 2026 earnings call transcript detailing quarterly financial results, pipeline progress, and management commentary on operations and outlook. Q2 earnings call transcript provides direct updates on financials and strategy that typically drive immediate stock movement and investor reassessment.

Mineralys Therapeutics maintains strong cash position per Q2 2026 earnings call highlights. Strong cash position provides operational runway but does not signal major strategic or product shifts.

Mineralys Therapeutics, Inc. released Q2 2026 earnings call summary covering financial results and company outlook. Quarterly earnings updates detail financial performance and outlook with moderate effect on operations and sentiment.

Mineralys Therapeutics reported Q2 financial results and provided pipeline updates on its hypertension candidate during the earnings call. Q2 earnings and pipeline updates can moderately shift near-term investor sentiment and valuation without altering long-term trajectory.

Mineralys Therapeutics reported second quarter 2026 financial results and issued a corporate update. Quarterly earnings releases and updates typically deliver moderate performance details that may shift near-term sentiment but rarely redefine long-term trajectory.

Mineralys Therapeutics (MLYS) approaches earnings with focus on Lorundrostat prospects amid market views that the stock remains undervalued. Pre-earnings analysis centered on core drug candidate may produce moderate short-term effects on valuation and sentiment.

Mineralys Therapeutics (MLYS) secures a $500 million funding deal with potential to turn its stock into a multibagger. A $500 million funding deal supplies major capital that can accelerate pipeline progress and lift long-term valuation prospects.

Mineralys Therapeutics' Lorundrostat shows expanding cardiovascular applications that strengthen MLYS positioning as a biotech investment opportunity. Lorundrostat cardiovascular expansion directly drives major shifts in Mineralys Therapeutics trajectory and investor sentiment.

Mineralys Therapeutics prices $150M public offering of common stock. Stock offering supplies fresh capital to operations yet dilutes existing shares, producing moderate effects on valuation and sentiment.

Mineralys Therapeutics presented late-breaking data on lorundrostat and heart failure risk biomarkers at the Endocrine Society Annual Meeting ENDO 2026. Clinical data presentation at major medical meeting signals potential influence on drug development perceptions and positioning.

Mineralys Therapeutics (MLYS) plans to repurchase potential royalties tied to Lorundrostat. Royalty repurchase changes Mineralys Therapeutics' future financial obligations and revenue split for Lorundrostat.

Mineralys Therapeutics buys out royalties on Lorundrostat and releases new data on the drug. Royalty buyout improves economics on lead asset Lorundrostat while new data supports further clinical progress.

Mineralys Therapeutics (MLYS) reported encouraging clinical trial data showing strong efficacy for Lorundrostat. Positive Lorundrostat efficacy data can drive major gains in valuation, development progress, and investor sentiment.

Mineralys Therapeutics priced a $150 million underwritten public offering of common stock. The $150 million equity raise materially extends cash runway and funds ongoing operations while diluting existing shareholders.

Mineralys Therapeutics priced a $150 million stock offering and repurchased Lorundrostat royalty obligations. Stock offering supplies cash and royalty repurchase trims future costs without altering drug development path.

Mineralys Therapeutics repurchased royalty obligations in its Tanabe License Agreement and secured concurrent financing. Royalty repurchase reduces future liabilities and concurrent financing adds capital, moderately affecting financial position.

Mineralys Therapeutics presented new data from the Phase 3 Launch-HTN trial of lorundrostat in hypertension patients with chronic kidney disease at the ESH 2026 meeting. Phase 3 trial data on lorundrostat directly supports potential regulatory progress and market positioning for the company's lead asset.

Mineralys Therapeutics will present new data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026). Phase 3 trial data presentation at major cardiology conference can drive significant investor interest and shift company valuation.

FDA accepted New Drug Application for lorundrostat from Mineralys Therapeutics (MLYS), a major milestone shifting the company's investment narrative from clinical-stage risks to potential commercialization in hypertension treatment. FDA NDA acceptance marks a transformative regulatory step for MLYS, paving way for possible approval and redefining its competitive position in hypertension.

Mineralys Therapeutics (MLYS) released Q1 earnings call highlights detailing financial results, pipeline updates, and strategic outlook. Q1 earnings call highlights deliver key financials, clinical progress, and guidance that could significantly sway investor sentiment and stock performance.

Mineralys Therapeutics, Inc. released Q1 2026 earnings call summary highlighting financial results, pipeline updates, and forward guidance. Q1 2026 earnings call summary details financial performance and strategic developments critical to future growth and investor confidence.

Mineralys Therapeutics (MLYS) released its Q1 2026 earnings call transcript, detailing quarterly financial results, operational updates, and management commentary on pipeline progress. Q1 2026 earnings transcript covers financial performance, clinical updates, and strategic outlook directly influencing MLYS stock trajectory and investor sentiment.

Mineralys Therapeutics (MLYS) reported first quarter 2026 financial results and provided a corporate update. Quarterly financial results and corporate updates often moderately affect biotech stock performance and investor sentiment.

Mineralys Therapeutics (MLYS) achieves FDA progress and hires key legal expert, prompting questions on reshaping cardiorenal commercialization strategy amid hypertension drug development. FDA progress and legal hire signal major regulatory and commercialization advancements for MLYS's cardiorenal pipeline.

Mineralys Therapeutics (MLYS) attracts investor attention due to positive progress in its lorundrostat program, a potential treatment for hypertension. Lorundrostat progress signals major pipeline advancement for MLYS, likely boosting stock performance and competitive positioning.

Mineralys Therapeutics (MLYS) biotech stock surges 365% following an $8 million investment targeting a drug with three planned NDA filings. 365% stock surge and $8M investment for drug with three planned NDAs promise to redefine MLYS competitive position and long-term prospects.

Mineralys Therapeutics (MLYS) advances with FDA on hypertension drug development, marking positive regulatory progress. FDA progress on hypertension treatment signals major regulatory milestone boosting MLYS pipeline and investor sentiment.

Mineralys Therapeutics, Inc. (MLYS) released Q4 2025 earnings call summary detailing financial results, operational updates, and forward-looking guidance. Q4 earnings call summary delivers major financial metrics, pipeline progress, and strategic outlook pivotal to MLYS investor sentiment and trajectory.

Mineralys Therapeutics (MLYS) delivered Q4 2025 earnings call highlights emphasizing strategic advances in pipeline development, financial position, and upcoming milestones. Strategic advances in Q4 2025 earnings call signal major pipeline progress and positioning shifts for MLYS.